NASDAQ:IBRX

Immunitybio Stock Earnings Reports

etoro logo Buy IBRX
*Your capital is at risk
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026

ImmunityBio Earnings Calls

Mar 31, 2026
-$0.0900 (-12.50%)
Release date May 07, 2026
EPS estimate -$0.0800
EPS actual -$0.0900
EPS Surprise -12.50%
Revenue estimate 43.069M
Revenue actual 44.206M
Revenue Surprise 2.64%
Dec 31, 2025
-$0.0600 (25.00%)
Release date Feb 23, 2026
EPS estimate -$0.0800
EPS actual -$0.0600
EPS Surprise 25.00%
Revenue estimate 38.361M
Revenue actual 38.285M
Revenue Surprise -0.198%
Sep 30, 2025
-$0.0700 (30.00%)
Release date Nov 04, 2025
EPS estimate -$0.100
EPS actual -$0.0700
EPS Surprise 30.00%
Revenue estimate 37.78M
Revenue actual 32.061M
Revenue Surprise -15.14%
Jun 30, 2025
Release date Aug 05, 2025
EPS estimate -$0.100
EPS actual -$0.100
Revenue estimate 31.882M
Revenue actual 26.425M
Revenue Surprise -17.12%

Last 4 Quarters for ImmunityBio

Below you can see how IBRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025
Release date Aug 05, 2025
Price on release $2.41
EPS estimate -$0.100
EPS actual -$0.100
Date Price
Jul 30, 2025 $2.56
Jul 31, 2025 $2.46
Aug 01, 2025 $2.37
Aug 04, 2025 $2.41
Aug 05, 2025 $2.41
Aug 06, 2025 $2.38
Aug 07, 2025 $2.41
Aug 08, 2025 $2.44
Aug 11, 2025 $2.47
4 days before -5.86%
4 days after 2.49%
On release day -1.24%
Change in period -3.52%
Sep 30, 2025 Beat
Release date Nov 04, 2025
Price on release $2.08
EPS estimate -$0.100
EPS actual -$0.0700
EPS surprise 30.00%
Date Price
Oct 29, 2025 $2.42
Oct 30, 2025 $2.36
Oct 31, 2025 $2.40
Nov 03, 2025 $2.26
Nov 04, 2025 $2.08
Nov 05, 2025 $2.15
Nov 06, 2025 $2.12
Nov 07, 2025 $2.13
Nov 10, 2025 $2.16
4 days before -14.05%
4 days after 3.85%
On release day 3.37%
Change in period -10.74%
Dec 31, 2025 Beat
Release date Feb 23, 2026
Price on release $9.83
EPS estimate -$0.0800
EPS actual -$0.0600
EPS surprise 25.00%
Date Price
Feb 17, 2026 $6.02
Feb 18, 2026 $8.54
Feb 19, 2026 $8.61
Feb 20, 2026 $8.70
Feb 23, 2026 $9.83
Feb 24, 2026 $11.55
Feb 25, 2026 $9.54
Feb 26, 2026 $9.55
Feb 27, 2026 $9.78
4 days before 63.29%
4 days after -0.509%
On release day 17.50%
Change in period 62.46%
Mar 31, 2026 Missed
Release date May 07, 2026
Price on release $7.76
EPS estimate -$0.0800
EPS actual -$0.0900
EPS surprise -12.50%
Date Price
May 01, 2026 $7.11
May 04, 2026 $7.43
May 05, 2026 $7.58
May 06, 2026 $8.38
May 07, 2026 $7.76
May 08, 2026 $8.51
May 11, 2026 $8.11
May 12, 2026 $8.12
May 13, 2026 $8.15
4 days before 9.14%
4 days after 5.03%
On release day 9.66%
Change in period 14.63%

ImmunityBio Earnings History

Earnings Calendar

FAQ

When is the earnings report for IBRX?
ImmunityBio, Inc. (IBRX) has scheduled its earnings report for Aug 04, 2026 after the markets close.

What is the IBRX price-to-earnings (P/E) ratio?
IBRX P/E ratio as of Jun 03, 2026 (TTM) is -8.69.

What is the IBRX EPS forecast?
The forecasted EPS (Earnings Per Share) for ImmunityBio, Inc. (IBRX) for the first fiscal quarter 2026 is -$0.0900.

What are ImmunityBio, Inc.'s retained earnings?
On its balance sheet, ImmunityBio, Inc. reported retained earnings of $44.21 million for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT IMMUNITYBIO, INC.
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE